AU2009324811B2 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
AU2009324811B2
AU2009324811B2 AU2009324811A AU2009324811A AU2009324811B2 AU 2009324811 B2 AU2009324811 B2 AU 2009324811B2 AU 2009324811 A AU2009324811 A AU 2009324811A AU 2009324811 A AU2009324811 A AU 2009324811A AU 2009324811 B2 AU2009324811 B2 AU 2009324811B2
Authority
AU
Australia
Prior art keywords
compound
formula
dyslipidaemia
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009324811A
Other languages
English (en)
Other versions
AU2009324811A1 (en
Inventor
Holly Esken
Beth Adams Norton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2009324811A1 publication Critical patent/AU2009324811A1/en
Application granted granted Critical
Publication of AU2009324811B2 publication Critical patent/AU2009324811B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009324811A 2008-12-08 2009-12-07 Novel compounds Ceased AU2009324811B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
US61/120,596 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds

Publications (2)

Publication Number Publication Date
AU2009324811A1 AU2009324811A1 (en) 2011-06-23
AU2009324811B2 true AU2009324811B2 (en) 2013-01-24

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324811A Ceased AU2009324811B2 (en) 2008-12-08 2009-12-07 Novel compounds

Country Status (22)

Country Link
US (3) US9163024B2 (enExample)
EP (1) EP2370440B1 (enExample)
JP (1) JP5666464B2 (enExample)
KR (1) KR101743783B1 (enExample)
CN (1) CN102245606B (enExample)
AU (1) AU2009324811B2 (enExample)
BR (1) BRPI0922134A2 (enExample)
CA (1) CA2746316C (enExample)
CY (1) CY1116032T1 (enExample)
DK (1) DK2370440T3 (enExample)
EA (1) EA020037B1 (enExample)
ES (1) ES2527354T3 (enExample)
HR (1) HRP20150026T1 (enExample)
IL (1) IL213032A (enExample)
MX (1) MX2011006022A (enExample)
PL (1) PL2370440T3 (enExample)
PT (1) PT2370440E (enExample)
RS (1) RS53777B1 (enExample)
SI (1) SI2370440T1 (enExample)
SM (1) SMT201500012B (enExample)
WO (1) WO2010068581A1 (enExample)
ZA (1) ZA201103397B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863888B (zh) * 2004-02-14 2012-07-18 葛兰素史密斯克莱有限责任公司 具有hm74a受体活性的药物
HRP20100725T1 (hr) 2005-08-10 2011-01-31 Glaxosmithkline Llc Derivati ksantina kao selektivni agonisti hm74a
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
AU2024229006A1 (en) 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
JP2003534238A (ja) * 1999-12-15 2003-11-18 スミスクライン・ビーチャム・コーポレイション シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
HRP20100725T1 (hr) 2005-08-10 2011-01-31 Glaxosmithkline Llc Derivati ksantina kao selektivni agonisti hm74a
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERGE, S.M. et al., Journal of Pharmaceutical Sciences, 1977, vol 66 (1), pages 1-19. *

Also Published As

Publication number Publication date
EP2370440B1 (en) 2014-11-12
AU2009324811A1 (en) 2011-06-23
US20170027945A1 (en) 2017-02-02
SMT201500012B (it) 2015-05-03
HRP20150026T1 (hr) 2015-02-13
JP5666464B2 (ja) 2015-02-12
BRPI0922134A2 (pt) 2015-08-18
WO2010068581A1 (en) 2010-06-17
CA2746316C (en) 2017-01-03
US20150366870A1 (en) 2015-12-24
SI2370440T1 (sl) 2015-02-27
MX2011006022A (es) 2011-06-28
PT2370440E (pt) 2015-01-14
KR20110097816A (ko) 2011-08-31
ES2527354T3 (es) 2015-01-22
IL213032A (en) 2015-02-26
EA020037B1 (ru) 2014-08-29
CA2746316A1 (en) 2010-06-17
CY1116032T1 (el) 2017-01-25
RS53777B1 (sr) 2015-06-30
EP2370440A1 (en) 2011-10-05
CN102245606A (zh) 2011-11-16
IL213032A0 (en) 2011-07-31
US9163024B2 (en) 2015-10-20
JP2012511028A (ja) 2012-05-17
KR101743783B1 (ko) 2017-06-05
EA201170783A1 (ru) 2011-12-30
DK2370440T3 (en) 2014-12-08
EP2370440A4 (en) 2012-05-30
PL2370440T3 (pl) 2015-05-29
CN102245606B (zh) 2014-08-20
ZA201103397B (en) 2012-01-25
US20110251218A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
AU2001291022B2 (en) Xanthine phosphodiesterase v inhibitors
CA2771123C (en) Substituted xanthine derivatives
US9493463B2 (en) Substituted xanthine derivatives
IL116831A (en) Anhydrous crystalline valaciclovir hydrochloride and its preparation
CZ307468B6 (cs) Nová krystalická a amorfní forma triazolo[4,5-d]pyrimidinové sloučeniny
JP2009504592A (ja) 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
US20170027945A1 (en) Novel Compounds
CA2771331A1 (en) Substituted xanthine derivatives
EP1575953A1 (en) Anhydrous crystalline form of valacyclovir hydrochloride
CN101282976A (zh) 作为选择性hm74a激动剂的黄嘌呤衍生物
JPWO1992006976A1 (ja) キサンチン誘導体
JPH0616668A (ja) キサンチン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired